SIGA Technologies, Inc. (SIGA) - 10-K Summary
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: SIGA is a commercial-stage pharmaceutical company focused on the health security market. Its lead product, TPOXX® (tecovirimat), is an antiviral approved by the FDA for the treatment of smallpox (oral and intravenous formulations). The company sells primarily to the U.S. Government (Strategic National Stockpile and Department of Defense) and international governments. In June 2024, SIGA reacquired primary international promotional rights from Meridian Medical Technologies, though Meridian retains limited rights in specific territories.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $138.7 million | $139.9 million |
| Net Income | $59.2 million | $68.1 million |
| Diluted EPS | $0.82 | $0.95 |
| Operating Cash Flow | $48.8 million | $94.8 million |
| Cash & Equivalents (End of Period) | $155.4 million | $150.1 million |
| Total Assets | $244.3 million | $254.4 million |
| Inventory | $49.6 million | $64.2 million |
| Deferred Revenue (IV TPOXX) | $10.3 million | $20.8 million |
Revenue Breakdown (2024):
- Product Sales & Supportive Services: $133.3 million (U.S. Gov: ~$100.1M; International: $23.0M; DoD: ~$10.1M).
- Research & Development Revenue: $5.4 million.
Material Changes vs. Prior Period
- Revenue Composition: While total revenue remained relatively flat, the mix shifted. Oral TPOXX sales to the U.S. Government decreased from $97.9M in 2023 to $73.9M in 2024, partially offset by the introduction of IV TPOXX sales ($26.2M) and increased international sales ($23.0M vs $21.3M).
- Cost of Sales: Increased significantly from $17.8M to $31.3M, driven by the higher manufacturing costs associated with the new IV TPOXX formulation.
- Profitability: Net income decreased by approximately 13% ($8.9M) due to higher operating expenses (SG&A increased $3.1M due to executive hiring) and the shift in revenue mix toward lower-margin IV products.
- Capital Allocation: The company paid a special dividend of $0.60 per share ($42.7M total) in 2024, compared to $0.45 per share ($32.1M) in 2023. The share repurchase program expired in 2023, and no repurchases occurred in 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook & Guidance:
- BARDA Contract: The 19C BARDA Contract contemplates up to $602.5 million in payments. As of Dec 31, 2024, $519.6M in options have been exercised. Approximately $31.2M in options remain unexercised, including a critical option for IV TPOXX manufacturing. BARDA has sole discretion on exercising these options.
- Regulatory Pipeline: SIGA is targeting a Supplemental NDA submission for smallpox post-exposure prophylaxis (PEP) within the next 12 months, pending CDC sample analysis.
- International Strategy: Following the reacquisition of international rights in June 2024, SIGA is building internal sales capabilities to expand beyond the U.S. Government.
Risks & Contingencies:
- Mpox Clinical Trials: Two major randomized, placebo-controlled trials (PALM 007 and STOMP) failed to meet their primary endpoints for efficacy in treating mpox. The company believes ongoing trials are likely to yield similar results, which may limit commercial opportunities for TPOXX in the mpox market.
- Government Dependence: A substantial percentage of future revenue depends on the U.S. Government exercising remaining options under the BARDA contract or entering new procurement contracts. Failure to secure these could materially harm the business.
- Manufacturing: SIGA relies entirely on third-party Contract Manufacturing Organizations (CMOs). Disruptions in the supply chain could delay deliveries and revenue recognition.
Investor Verification Checklist
- BARDA Option Exercise: Verify the status of the remaining unexercised options (approx. $31.2M potential), specifically the IV TPOXX options, as these are critical for future revenue visibility.
- Mpox Commercial Viability: Assess the impact of the failed PALM 007 and STOMP trial results on the potential for non-government commercial sales of TPOXX for mpox.
- International Sales Transition: Monitor the success of SIGA's internal international sales team following the termination of Meridian's exclusive rights in June 2024.
- IV TPOXX Margins: Review the gross margin profile of IV TPOXX (estimated <40% if remaining options are exercised) versus oral TPOXX to understand long-term profitability trends.
- PEP Submission Timeline: Track the progress of the CDC sample analysis required for the smallpox PEP Supplemental NDA submission.